We are live on
!
Find out more
KCM
Knoll Capital Management Portfolio holdings
AUM
$180M
1-Year Est. Return
66.11%
This Fund
S&P 500
This Quarter
Est. Return
-6.21%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$148M
AUM Growth
-$12.3M
(-7.7%)
Cap. Flow
+$11.9M
Cap. Flow
% of AUM
8.04%
Top 10 Holdings %
Top 10 Hldgs %
74.02%
Holding
35
New
1
Increased
2
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$7.64M |
| 2 |
Altimmune
ALT
|
+$4.09M |
| 3 |
CRDL
Cardiol Therapeutics
CRDL
|
+$212K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.41% |
| 2 | Materials | 20.1% |
| 3 | Industrials | 1.98% |
| 4 | Consumer Staples | 1.26% |
| 5 | Financials | 0.86% |
Similar funds
MGWA
AW
FBC
AIC
AG
PCA
HIC
FFA
Knoll Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, Knoll Capital Management held 35 positions worth $148M, down 7.7% from $161M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Knoll Capital Management deployed $11.9M of net new capital in Q2 2024, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Cardiol Therapeutics: 100,000 shares worth $202K.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 72% a quarter earlier, followed by Materials and Industrials.
- Knoll Capital Management's largest Q2 2024 buy was Cardiol Therapeutics: 100,000 shares worth $202K.
- Knoll Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2024, an estimated $7.64M increase.
- Knoll Capital Management's ten largest holdings make up 74% of its $148M portfolio in Q2 2024.
- Knoll Capital Management opened 1 new position and closed 0 in Q2 2024.
- Knoll Capital Management's portfolio value fell 7.7% quarter-over-quarter to $148M.
Based on Knoll Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.